JPH0254747B2 - - Google Patents
Info
- Publication number
- JPH0254747B2 JPH0254747B2 JP61020164A JP2016486A JPH0254747B2 JP H0254747 B2 JPH0254747 B2 JP H0254747B2 JP 61020164 A JP61020164 A JP 61020164A JP 2016486 A JP2016486 A JP 2016486A JP H0254747 B2 JPH0254747 B2 JP H0254747B2
- Authority
- JP
- Japan
- Prior art keywords
- adsorbent
- body fluid
- fluid purification
- container
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003463 adsorbent Substances 0.000 claims description 37
- 210000001124 body fluid Anatomy 0.000 claims description 30
- 239000010839 body fluid Substances 0.000 claims description 29
- 238000000746 purification Methods 0.000 claims description 28
- 238000001179 sorption measurement Methods 0.000 claims description 21
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 5
- 239000005977 Ethylene Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical group CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical group 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BJELTSYBAHKXRW-UHFFFAOYSA-N 2,4,6-triallyloxy-1,3,5-triazine Chemical compound C=CCOC1=NC(OCC=C)=NC(OCC=C)=N1 BJELTSYBAHKXRW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- -1 cyanogen halide Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
【発明の詳細な説明】
発明の背景
［技術分野］
本発明は新規な体液浄化用吸着材および該吸着
材を利用した体液浄化用吸着装置に関するもので
ある。BACKGROUND OF THE INVENTION [Technical Field] The present invention relates to a novel adsorbent for body fluid purification and an adsorption device for body fluid purification using the adsorbent.
ビリルビン等血中のアルブミン抱合性毒性物質
を除去するには血漿交換が有効であることが知ら
れているが、血漿交換に必要な新鮮凍結血漿を大
量に得ることは困難であり、また肝炎等の危険も
ある。 Plasma exchange is known to be effective in removing albumin-conjugated toxic substances from the blood such as bilirubin, but it is difficult to obtain a large amount of fresh frozen plasma necessary for plasma exchange, and it is also difficult to obtain a large amount of fresh frozen plasma necessary for plasma exchange. There is also a danger of
そこで自己血漿中のアルブミンを選択的に除去
してそれに抱合されている毒性物質を除き、浄化
した自己血漿を再利用する治療法が開発されつつ
ある。本発明の体液浄化用吸着材および吸着装置
はこのような治療法に使用されるものである。 Therefore, therapeutic methods are being developed that selectively remove albumin from autologous plasma, remove toxic substances conjugated to it, and reuse the purified autologous plasma. The body fluid purification adsorbent and adsorption device of the present invention are used in such treatment methods.
［先行技術およびその問題点］
従来血液中のアルブミン抱合性毒性物質の除去
には活性炭等の吸着材が使用されていた。活性炭
は低分子物質の吸着能は優れているが、タンパク
質のような高分子物質の吸着能は十分ではなく、
また吸着の選択性にも乏しい欠点があつた。[Prior Art and its Problems] Conventionally, adsorbents such as activated carbon have been used to remove albumin-conjugated toxic substances from blood. Activated carbon has an excellent adsorption capacity for low-molecular substances, but its adsorption capacity for high-molecular substances such as proteins is not sufficient.
It also had the disadvantage of poor adsorption selectivity.
発明の目的
本発明は血漿中のアルブミンを収率よく、しか
も選択的に吸着することによりアルブミン抱合性
毒性を除去する体液浄化用吸着材を提供すること
を目的とする。 OBJECTS OF THE INVENTION An object of the present invention is to provide an adsorbent for body fluid purification that removes albumin-conjugated toxicity by selectively adsorbing albumin in plasma with good yield.
本発明はさらに、上記体液浄化用吸着材を利用
した体液浄化用吸着装置を提供することを目的と
する。 A further object of the present invention is to provide an adsorption device for body fluid purification using the above-mentioned adsorbent for body fluid purification.
本発明によれば、次の各項に記載の体液浄化用
吸着材および吸着装置が提供される。 According to the present invention, there are provided an adsorbent for body fluid purification and an adsorption device described in the following sections.
(1) 不溶性担体にtert−アルキルアミンまたはト
リアルキルクロルシランを結合させたことを特
徴とする体液浄化用吸着材。(1) An adsorbent for body fluid purification characterized by having tert-alkylamine or trialkylchlorosilane bound to an insoluble carrier.
(2) 前記不溶性担体が親水性架橋担体である第１
項記載の体液浄化用吸着材。(2) A first method in which the insoluble carrier is a hydrophilic crosslinked carrier.
Adsorbent material for body fluid purification as described in section.
(3) 前記不溶性担体が親水性架橋ビニル担体であ
る第１項または第２項記載の体液浄化用吸着
材。(3) The adsorbent for body fluid purification according to item 1 or 2, wherein the insoluble carrier is a hydrophilic crosslinked vinyl carrier.
(4) 前記不溶性担体が親水性ビニル重合体にエチ
レン系架橋材を反応させて３次元構造としたも
のである第１項または第３項記載の体液浄化用
吸着材。(4) The adsorbent for body fluid purification according to item 1 or 3, wherein the insoluble carrier has a three-dimensional structure obtained by reacting a hydrophilic vinyl polymer with an ethylene crosslinking material.
(5) 前記tert−アルキルアミンがtert−ブチルア
ミンである第１項記載の体液浄化用吸着材。(5) The adsorbent for body fluid purification according to item 1, wherein the tert-alkylamine is tert-butylamine.
(6) 流体の導出入口を有する容器と該容器内に充
填された吸着材と前記容器に設けられた該吸着
材の流出防止手段とを有し、前記吸着材は不溶
性担体にtert−アルキルアミンまたはトリアル
キルクロルシランを結合させたものであること
を特徴とする体液浄化用吸着装置。(6) A container having an inlet and an inlet for a fluid, an adsorbent filled in the container, and a means for preventing the adsorbent from flowing out provided in the container, and the adsorbent contains a tert-alkylamine in an insoluble carrier. or an adsorption device for body fluid purification, characterized in that it is an adsorption device to which trialkylchlorosilane is bonded.
(7) 前記装置は精製水で充填され、オートクレー
ブ滅菌されている第６項記載の体液浄化用吸着
装置。(7) The adsorption device for body fluid purification according to item 6, wherein the device is filled with purified water and sterilized in an autoclave.
(8) 前記流出防止手段が前記容器内に設けられた
フイルターである第６項記載の体液浄化用吸着
装置。(8) The adsorption device for bodily fluid purification according to item 6, wherein the outflow prevention means is a filter provided in the container.
発明の具体的説明
上記の目的を達成するため、本発明は不溶性担
体にバルキーな構造を有する化合物を結合させた
ものからなる体液浄化用吸着材よりなる。不溶性
担体は親水性架橋担体、特に親水性架橋ビニル担
体が好ましい。親水性架橋ビニル担体は親水性ビ
ニル重合体にエチレン系架橋材を反応させて３次
元構造としたものが特に好ましい。 DETAILED DESCRIPTION OF THE INVENTION In order to achieve the above object, the present invention comprises an adsorbent for body fluid purification comprising an insoluble carrier bound to a compound having a bulky structure. The insoluble carrier is preferably a hydrophilic crosslinked carrier, particularly a hydrophilic crosslinked vinyl carrier. It is particularly preferable that the hydrophilic crosslinked vinyl carrier has a three-dimensional structure obtained by reacting a hydrophilic vinyl polymer with an ethylene crosslinking material.
親水性ビニル重合体は幹ポリマーであり、好ま
しい例として酢酸ビニル、ビニルアルコール等の
ホモもしくはコポリマーがあげられる。エチレン
系架橋剤としてはトリアジン環を有するエチレン
系架橋剤例えばトリアリルイソシアヌレート、ト
リアリルシアヌレート等が好適に使用される。架
橋反応はそれ自体公知の方法によつて実施され
る。例えばビニル重合体と架橋剤を適当な有機溶
媒（例えば酢酸エチル）に溶解させた有機溶媒溶
液とポリビニルアルコール等を分散剤として添加
した水溶液を混合し、懸濁させ、該懸濁液を60〜
80℃で12〜18時間反応させる。かくして得られる
共重合体は粒子状であるのでさらに成形すること
なくそのまま吸着材担体部分とすることができ
る。その場合、本発明の目的から粒子の直径は50
〜3000μｍ、特に100〜500μｍで吸着限界は分子
量１万〜20万、特に３万〜10万が好ましい。上記
担体部分にリガンド部分としてバルキーな構造を
有する化合物を結合させる。tert−アルキルアミ
ンとしては例えばtert−ブチルアミン、トリアル
キルクロルシランとしては例えばトリメチルクロ
ルシラン等が使用される。これらの化合物を担体
部分と結合させるにはそれ自体公知の反応が使用
される。例えばエポキシまたはハロゲン化シアン
を用いる方法、担体中に水酸基がある場合には直
接反応させる方法等があげられる。 The hydrophilic vinyl polymer is a backbone polymer, and preferred examples include homopolymers or copolymers of vinyl acetate, vinyl alcohol, and the like. As the ethylene crosslinking agent, ethylene crosslinking agents having a triazine ring, such as triallyl isocyanurate and triallyl cyanurate, are preferably used. The crosslinking reaction is carried out by methods known per se. For example, an organic solvent solution in which a vinyl polymer and a crosslinking agent are dissolved in a suitable organic solvent (e.g., ethyl acetate) and an aqueous solution in which polyvinyl alcohol or the like is added as a dispersant are mixed and suspended, and the suspension is
Incubate at 80°C for 12-18 hours. Since the copolymer thus obtained is in the form of particles, it can be used as an adsorbent carrier portion without further molding. In that case, for the purposes of the present invention, the particle diameter should be 50
~3,000 μm, particularly 100 to 500 μm, and the adsorption limit is preferably a molecular weight of 10,000 to 200,000, particularly preferably 30,000 to 100,000. A compound having a bulky structure is bonded to the carrier portion as a ligand portion. As the tert-alkylamine, for example, tert-butylamine is used, and as the trialkylchlorosilane, for example, trimethylchlorosilane is used. Reactions known per se are used to link these compounds to carrier moieties. Examples include a method using epoxy or cyanogen halide, and a method in which a hydroxyl group is directly reacted when the carrier has a hydroxyl group.
本発明の吸着材は、粒子状、繊維状、中空糸
状、膜状等いずれの公知の形状でも用いうるが、
血液、血漿の通液性、吸着材調製時の取扱いの簡
便性などの点から粒子状担体が特に好ましく用い
られる。さらに粒子状であつて、多孔質体である
ことが好ましい。 The adsorbent of the present invention can be used in any known shape such as particulate, fibrous, hollow fiber, or membrane.
Particulate carriers are particularly preferably used from the viewpoint of permeability to blood and plasma, ease of handling during preparation of the adsorbent, and the like. Furthermore, it is preferably particulate and porous.
多孔質体を製造する方法としては、共重合体の
成形時に、後に抽出され多孔部分を形成する間隙
形成物質を混合させ、後に、その間隙形成物質の
良溶媒にて洗浄することにより、多孔質体を得る
ことができる。間隙形成物質としては、ポリマー
例えば、ポリ酢酸ビニル等が使用できる。そし
て、形成される孔は、孔径300〜3000Åの貫通孔
であることが好ましい。より好ましくは、孔径が
400〜1000Åである。 The method for manufacturing a porous body is to mix a pore-forming substance that will be extracted later and form a porous part during molding of the copolymer, and then wash it with a good solvent for the pore-forming substance to form a porous body. You can get a body. As the gap-forming substance, polymers such as polyvinyl acetate can be used. The holes formed are preferably through holes with a diameter of 300 to 3000 Å. More preferably, the pore size is
It is 400 to 1000 Å.
次に添付図面を参照しつつ本発明の装置につい
て説明する。 Next, the apparatus of the present invention will be explained with reference to the accompanying drawings.
第１図は本発明装置の一例を示す断面図であ
る。本装置は両端に入口４および出口５を有する
容器１とその内部に収容された吸着材２と入口４
および出口５に上記吸着材２の流出防止手段であ
るフイルター３，３′が設けられている。フイル
ター３，３′は吸着材の流出のみならず、その破
片等が体液に入り体内に流れ込むのを防ぐ作用も
行つている。体液は、体液導入口４より導入さ
れ、吸着材２で処理された後、体液導出口５から
導出される。吸着材はフイルター３，３′により
容器内に保持されている。 FIG. 1 is a sectional view showing an example of the device of the present invention. This device consists of a container 1 having an inlet 4 and an outlet 5 at both ends, an adsorbent 2 housed inside the container, and an inlet 4.
Filters 3 and 3' are provided at the outlet 5 to prevent the adsorbent 2 from flowing out. The filters 3, 3' not only prevent the adsorbent from flowing out, but also prevent its fragments from entering the body fluid and flowing into the body. The body fluid is introduced through the body fluid inlet 4, treated with the adsorbent 2, and then led out through the body fluid outlet 5. The adsorbent is retained in the container by filters 3, 3'.
本発明の吸着装置は、使用の便宜のため、蒸留
水や生理食塩水等の精製水で充填され、オートク
レーブ滅菌されて製品とするのが望ましい。 For convenience of use, the adsorption device of the present invention is desirably filled with purified water such as distilled water or physiological saline and sterilized in an autoclave to produce a product.
第２図は、本発明の吸着装置を用いて血液浄化
治療を行う場合の１例を示す概略図である。血液
は血液導入口６より導入され、ポンプ７を通つて
血漿分離装置８へ供給され、血球と血漿に分離さ
れる。分離された血漿はポンプ７′を通つて、吸
着容器１に供給され、吸着処理された後に血漿・
血球混合装置９で血球と混合されて血液導出口１
０より導出される。 FIG. 2 is a schematic diagram showing an example of blood purification treatment using the adsorption device of the present invention. Blood is introduced through a blood inlet 6, supplied to a plasma separator 8 through a pump 7, and separated into blood cells and plasma. The separated plasma is supplied to the adsorption container 1 through the pump 7', and after being adsorbed, the plasma and
The blood cells are mixed with the blood cells in the blood cell mixing device 9 and the blood is discharged through the blood outlet port 1.
Derived from 0.
本発明の装置を体外循環で用いる場合には、大
略次の二通りの方法がある。１つには、体内から
取り出した血液を遠心分離器もしくは膜型あるい
は中空糸型血漿分離器を使用して、血漿成分と血
球成分とに分離した後、血漿成分を該装置に通過
させ、浄化した後、血球成分と合わせて体内に戻
す方法であり、他の１つは体内から取り出した血
液を直接該装置に通過させ、浄化する方法であ
る。 When the device of the present invention is used for extracorporeal circulation, there are roughly two methods as follows. First, blood taken from the body is separated into plasma components and blood cell components using a centrifuge or a membrane or hollow fiber plasma separator, and then the plasma components are passed through the device for purification. There is a method in which the blood is then returned to the body together with blood cell components, and the other method is to directly pass the blood taken out from the body through the device and purify it.
体液の通過方法としては、臨床上の必要に応
じ、あるいは設備の設置状況に応じて、連続的に
通液してもよいし、また断続的に通液使用しても
よい。 The method for passing body fluids may be continuous or intermittent, depending on clinical needs or the installation status of the equipment.
次に実施例を示して本発明をさらに具体的に説
明する。 Next, the present invention will be explained in more detail with reference to Examples.
実施例
トリアリルイソシアヌレート・酢酸ビニル共重
合体をケン化したゲルにジメチルスルホキシド中
でエピクロルヒドリンを反応させ、活性化ゲルを
生成した。このゲルのエポキシ基密度は1.2ｍ
mol／ｇ樹脂であつた。この活性化ゲル２ｇに
tert−ブチルアミン0.12ｇを含む0.1M炭酸バツフ
アー（PH10.0）を加え、50℃で18時間振盪撹拌を
行なつた。未反応のエポキシ基をブロツキングす
るため、0.05Mトリス（ヒドロキシメチル）アミ
ノメタン水溶液30mlを加え、５時間振盪撹拌を行
なつた。反応終了後、ゲルを十分に水洗し、吸着
材（tert−ブチル化ゲル）を得た。ゲル中のtert
−ブチル基濃度は368μmol／ｇ樹脂であつた。Example A gel obtained by saponifying triallyl isocyanurate/vinyl acetate copolymer was reacted with epichlorohydrin in dimethyl sulfoxide to produce an activated gel. The epoxy group density of this gel is 1.2m
mol/g resin. 2g of this activated gel
A 0.1 M carbonate buffer (PH 10.0) containing 0.12 g of tert-butylamine was added, and the mixture was shaken and stirred at 50°C for 18 hours. In order to block unreacted epoxy groups, 30 ml of 0.05M tris(hydroxymethyl)aminomethane aqueous solution was added, and the mixture was shaken and stirred for 5 hours. After the reaction was completed, the gel was thoroughly washed with water to obtain an adsorbent (tert-butylated gel). tert in gel
-Butyl group concentration was 368 μmol/g resin.
上記吸着材300mgにγ−グロブリン（１mg／ml）
およびアルブミン（１mg／ml）を含む評価用水溶
液３mlを加え、37℃で１時間、振盪インキユベー
トを行なつた。評価用水溶液中の各蛋白質の定量
を行ない、回収率を算出した。結果は次のとおり
であつた。 γ-globulin (1 mg/ml) to 300 mg of the above adsorbent
3 ml of an aqueous evaluation solution containing albumin (1 mg/ml) was added, and the mixture was incubated with shaking at 37° C. for 1 hour. Each protein in the aqueous solution for evaluation was quantified and the recovery rate was calculated. The results were as follows.
回収率（％）
アルブミン 49
γ−グロブリン 80
上記の結果から本発明の吸着材はアルブミンを
高収率でかつ選択的に吸着することが明らかであ
る。 Recovery rate (%) Albumin 49 γ-globulin 80 From the above results, it is clear that the adsorbent of the present invention selectively adsorbs albumin at a high yield.
発明の効果
本発明の体液浄化用吸着材は不溶性担体にバル
キーな構造を有する化合物を結合させたものから
なり、アルブミンを高収率でかつ選択的に吸着す
ることによりアルブミン抱合性毒性物質の除去を
高率かつ選択的に行うことができる。 Effects of the Invention The adsorbent for body fluid purification of the present invention is made of an insoluble carrier bound to a compound having a bulky structure, and removes albumin-conjugated toxic substances by selectively adsorbing albumin in a high yield. can be performed selectively and at a high rate.
第１図は、本発明の吸着装置の一例を示す断面
図である。第２図は、本発明の吸着装置を用いて
血液浄化治療を行う場合の１例を示す概略図であ
る。
１……容器、２……吸着材、３，３′……フイ
ルター、４……入口、５……出口、６……血液導
入口、７，７′……ポンプ、８……血漿分離装置、
９……血球混合装置、１０……血液導出口。
FIG. 1 is a sectional view showing an example of the adsorption device of the present invention. FIG. 2 is a schematic diagram showing an example of blood purification treatment using the adsorption device of the present invention. 1... Container, 2... Adsorbent, 3, 3'... Filter, 4... Inlet, 5... Outlet, 6... Blood inlet, 7, 7'... Pump, 8... Plasma separation device ,
9...Blood cell mixing device, 10...Blood outlet.
Claims (1)
リアルキルクロルシランを結合させたことを特徴
とする体液浄化用吸着材。 ２ 前記不溶性担体が親水性架橋担体である特許
請求の範囲第１項記載の体液浄化用吸着材。 ３ 前記不溶性担体が親水性架橋ビニル担体であ
る特許請求の範囲第１項または第２項記載の体液
浄化用吸着材。 ４ 前記不溶性担体が親水性ビニル重合体にエチ
レン系架橋材を反応させて３次元構造としたもの
である特許請求の範囲第１項または第３項記載の
体液浄化用吸着材。 ５ 前記tert−アルキルアミンがtert−ブチルア
ミンである特許請求の範囲第１項記載の体液浄化
用吸着材。 ６ 流体の導出入口を有する容器と該容器内に充
填された吸着材と前記容器に設けられた該吸着材
の流出防止手段とを有し、前記吸着材は不溶性担
体にtert−アルキルアミンまたはトリアルキルク
ロルシランを結合させたものであることを特徴と
する体液浄化用吸着装置。 ７ 前記装置は精製水で充填され、オートクレー
ブ滅菌されている特許請求の範囲第６項記載の体
液浄化用吸着装置。 ８ 前記流出防止手段が前記容器内に設けられた
フイルターである特許請求の範囲第６項記載の体
液浄化用吸着装置。[Scope of Claims] 1. An adsorbent for body fluid purification, characterized in that tert-alkylamine or trialkylchlorosilane is bonded to an insoluble carrier. 2. The adsorbent for body fluid purification according to claim 1, wherein the insoluble carrier is a hydrophilic crosslinked carrier. 3. The adsorbent for body fluid purification according to claim 1 or 2, wherein the insoluble carrier is a hydrophilic crosslinked vinyl carrier. 4. The adsorbent for body fluid purification according to claim 1 or 3, wherein the insoluble carrier has a three-dimensional structure obtained by reacting a hydrophilic vinyl polymer with an ethylene crosslinking material. 5. The adsorbent for body fluid purification according to claim 1, wherein the tert-alkylamine is tert-butylamine. 6 A container having a fluid inlet/outlet, an adsorbent filled in the container, and a means for preventing the adsorbent from flowing out provided in the container, and the adsorbent is an insoluble carrier containing tert-alkylamine or tritriamine. An adsorption device for body fluid purification, characterized in that it is an adsorption device in which alkylchlorosilane is bonded. 7. The adsorption device for body fluid purification according to claim 6, wherein the device is filled with purified water and sterilized in an autoclave. 8. The adsorption device for body fluid purification according to claim 6, wherein the outflow prevention means is a filter provided in the container.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61020164A JPS62179469A (en) | 1986-02-03 | 1986-02-03 | Adsorbing material and apparatus for purifying body fluids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61020164A JPS62179469A (en) | 1986-02-03 | 1986-02-03 | Adsorbing material and apparatus for purifying body fluids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62179469A JPS62179469A (en) | 1987-08-06 |
| JPH0254747B2 true JPH0254747B2 (en) | 1990-11-22 |
Family
ID=12019514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61020164A Granted JPS62179469A (en) | 1986-02-03 | 1986-02-03 | Adsorbing material and apparatus for purifying body fluids |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62179469A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57122875A (en) * | 1981-01-22 | 1982-07-30 | Asahi Chemical Ind | Immunity adsorbing material and adsorbing device |
-
1986
- 1986-02-03 JP JP61020164A patent/JPS62179469A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57122875A (en) * | 1981-01-22 | 1982-07-30 | Asahi Chemical Ind | Immunity adsorbing material and adsorbing device |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62179469A (en) | 1987-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6145773A (en) | Material and apparatus for purifying body fluids | |
| JPS6311167A (en) | Non-biological adsorbent and removal of unnecessary factor in plasma using the same | |
| JPS59193135A (en) | Adsorbing body | |
| JP2814399B2 (en) | Adsorber for whole blood processing | |
| JPH0254747B2 (en) | ||
| JPS6319214B2 (en) | ||
| CA1309020C (en) | Extracorporeal removal of immunoglobulin-g and circulating immune complexes | |
| Karoor et al. | Immunoaffinity removal of xenoreactive antibodies using modified dialysis or microfiltration membranes | |
| JPH0114791B2 (en) | ||
| JP2649224B2 (en) | Sterilization method for body fluid treatment device and sterilized body fluid treatment device | |
| US6309999B1 (en) | Process for the preparation of an immunoadsorbent matrix | |
| JPS6087854A (en) | Adsorbent for purifying blood | |
| JPS6253669A (en) | Material and apparatus for adsorbing immunoglobulin substance | |
| JPH025098B2 (en) | ||
| JPS6226073A (en) | Method and apparatus for direct infusion and adsorption of blood | |
| JPS6111054A (en) | Blood purification system | |
| JPS639450A (en) | Body fluid component separating material and body fluid component separator equipped therewith | |
| JPS6259976B2 (en) | ||
| JPH01158970A (en) | Immunoglobulin adsorbing material for direct blood perfusion and adsorbing apparatus | |
| JPH024301B2 (en) | ||
| JPH0523395A (en) | Blood purifying adsorbent | |
| JPH0316639A (en) | Adsorbent and removing device using the same | |
| JPS61253071A (en) | Blood purifying apparatus | |
| JP2726662B2 (en) | Adsorbent and removal device using the same | |
| JPH08173528A (en) | Blood processing system |